Is atropine (antimuscarinic) ophthalmic solution administered in both eyes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Atropine ophthalmic solution is administered in the nonamblyopic eye, not both eyes, for the treatment of amblyopia in children. The most recent and highest quality study, published in 2023 in the journal Ophthalmology 1, supports the use of atropine 1% solution in the fellow eye as an effective method of treatment for mild to moderate amblyopia in children.

Key Points

  • Atropine 1% ophthalmic solution is used to produce cycloplegia of the nonamblyopic eye, which helps to improve vision in the amblyopic eye 1.
  • The treatment works best when the nonamblyopic eye is hyperopic, as the cycloplegia optically defocuses the nonamblyopic eye 1.
  • Atropine appears to be as effective as occlusion in treating amblyopia, with a benefit that is stable through 15 years of age 1.
  • Pharmacological treatment has been prescribed using a variety of dosage schemes, including daily dosing and twice weekly dosing, with modest improvement reported in children with severe amblyopia 1.

Administration and Side Effects

  • Atropine 1% solution is typically administered to the nonamblyopic eye, with a prescribed dose of twice weekly for children with moderate amblyopia 1.
  • Pharmacological treatment of amblyopia may have ocular and systemic side effects, including transient reduction of VA in the nonamblyopic eye, reverse amblyopia, and systemic effects such as dryness of the mouth and skin, fever, delirium, and tachycardia 1.
  • Monitoring the VA of each eye of a child being treated is essential, and fellow eye acuity can be assessed more accurately when atropine is discontinued at least 1 week before testing 1.

From the Research

Administration of Atropine Ophthalmic Solution

  • Atropine ophthalmic solution is administered in both eyes, as seen in studies where it was used to induce cycloplegic refraction in children with hypermetropia 2, 3.
  • In one study, atropine 1% was administered twice in each eye to induce cycloplegic refraction 2.
  • Another study used atropine ointment 1% administered twice a day for 3 days in both eyes to induce cycloplegia 3.
  • A study on the effect of low-dose atropine on binocular vision and accommodation in children also administered atropine eye drops in both eyes 4.

Specific Studies

  • A 2016 study compared the cycloplegic effect of atropine with cyclopentolate and tropicamide combination in children with hypermetropia, and administered atropine 1% in both eyes 2.
  • A 2023 study compared cycloplegia induced by cyclopentolate 1% to that induced by atropine 1% in children, and administered atropine ointment 1% in both eyes 3.
  • A 2023 study on the effect of low-dose atropine on binocular vision and accommodation in children administered atropine eye drops in both eyes, with concentrations of 0.01%, 0.03%, and 0.05% 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cycloplegic effect of atropine compared with cyclopentolate-tropicamide combination in children with hypermetropia.

Nigerian medical journal : journal of the Nigeria Medical Association, 2016

Research

Effect of Low-dose Atropine on Binocular Vision and Accommodation in Children Aged 6 to 17 Years.

Optometry and vision science : official publication of the American Academy of Optometry, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.